KYTX Kyverna Therapeutics, Inc. - 8-K

Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 27, 2026, Kyverna Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). Of the 60,530,293 shares of the Company’s common stock outstanding as of March 30, 2026, the record date for the Annual Meeting, 43,987,007 shares were represented at the Annual Meeting virtually or by proxy, constituting approximately 73% of the outstanding shares entitled to vote and constituting a quorum for the transaction of business.

At the Annual Meeting, the Company’s stockholders considered two proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 13, 2026.

Set forth below is a brief description of each proposal voted upon at the Annual Meeting and the voting results with respect to each proposal.

Proposal No. 1. To elect two Class II directors to hold office until the Company’s 2029 annual meeting of stockholders or until their successors are elected and qualified:

Director Nominee

Votes For

Votes Withheld

Broker Non-Votes

Ian Clark

31,505,902

3,255,231

9,225,874

Christi Shaw

34,528,865

232,268

9,225,874

As a result, the Company’s stockholders voted to elect Ian Clark and Christi Shaw as Class II directors to serve until the Company’s 2029 annual meeting of stockholders or until his or her respective successor is duly elected and qualified.

Proposal No. 2. To ratify the appointment by the Audit Committee of the Company’s Board of Directors of BDO USA, P.C., as the independent registered public accounting firm and independent auditor of the Company for the year ending December 31, 2026:

Votes For

Votes Against

Abstentions

43,830,300

80,223

76,484

As a result, the Company’s stockholders voted to ratify the appointment of BDO USA, P.C., as the independent registered public accounting firm and independent auditor of the Company for the year ending December 31, 2026.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

104

Cover Page Interactive Data File (embedded with the Inline XBRL document).